Search Results

You are looking at 41 - 50 of 1,450 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Narek Shaverdian, Erin F. Gillespie, Elaine Cha, Soo Young Kim, Stephanie Benvengo, Fumiko Chino, Jung Julie Kang, Yuelin Li, Thomas M. Atkinson, Nancy Lee, Charles M. Washington, Oren Cahlon, and Daniel R. Gomez

. Statistical Analysis All completed surveys were analyzed. There were no additional inclusion or exclusion criteria. A predefined statistical plan was used to minimize inflation of type I error. Patient characteristics and survey responses for office visit

Full access

Elliott K. Yee, Natalie G. Coburn, Laura E. Davis, Alyson L. Mahar, Victoria Zuk, Vaibhav Gupta, Ying Liu, Craig C. Earle, and Julie Hallet

baseline characteristics of the cohort and outcomes, stratified by distance category and geographic region of residence. Patients were linked to geographic regions using the PCCF. Choropleth maps of the primary outcomes across each geographic region

Full access

Héctor G. van den Boorn, Ameen Abu-Hanna, Nadia Haj Mohammad, Maarten C.C.M. Hulshof, Suzanne S. Gisbertz, Bastiaan R. Klarenbeek, Marije Slingerland, Laurens V. Beerepoot, Tom Rozema, Mirjam A.G. Sprangers, Rob H.A. Verhoeven, Martijn G.H. van Oijen, Koos H. Zwinderman, and Hanneke W.M. van Laarhoven

options. Furthermore, prediction models for the metastatic setting are scarce. We recently developed 2 models to predict survival in patients with metastatic esophageal or gastric cancer based on tumor, patient, and treatment characteristics. 13

Full access

Adam J. Olszewski, Kalyan C. Mantripragada, and Jorge J. Castillo

.1 (StataCorp LP, College Station, TX) and report estimates with 95% CIs. Results Patient Characteristics Among the 5,530 eligible patients (with a median age of 76 years) treated with outpatient rituximab-based immunochemotherapy in 2003

Full access

Jeremy D. Kratz, Nataliya V. Uboha, Sam J. Lubner, Daniel L. Mulkerin, Linda Clipson, Yanyao Yi, Menggang Yu, Kristina A. Matkowskyj, Noelle K. LoConte, and Dustin A. Deming

using the Breslow method. Results Sidedness Predicts Outcomes to Anti-EGFR Therapy in the Treatment-Refractory Setting A total of 62 patients were available for analysis, with baseline characteristics stratified by primary tumor sidedness

Full access

Andrew D. Zelenetz

highlighted the second-generation BCL-2 inhibitor venetoclax (ABT-199). Early studies with venetoclax have confirmed its activity and the durability of Figure 2 Ideal Characteristics of Immunoconjugates. responses in patients with relapsed

Full access

Siew Tzuh Tang, Jen-Shi Chen, Wen-Chi Chou, Wen-Cheng Chang, Chiao-En Wu, Chia-Hsun Hsieh, Ming-Chu Chiang, and Mei-Ling Kuo

committee approved the research protocol. All participants signed informed consents. Measures Data were collected on anxiety symptoms and 5 groups of variables (demographics, disease-related characteristics, disease burden, perceived burden to others

Full access

Mostafa R. Mohamed, Erika Ramsdale, Kah Poh Loh, Huiwen Xu, Amita Patil, Nikesha Gilmore, Spencer Obrecht, Megan Wells, Ginah Nightingale, Katherine M. Juba, Bryan Faller, Adedayo Onitilo, Thomas Bradley, Eva Culakova, Holly Holmes, and Supriya G. Mohile

the potential for collinearity in multivariate analyses, cognitive impairment was not included as a separate variable in our models. Statistical Approach For each of the 3 outcome measures, we used the receiver operating characteristic (ROC) curve

Full access

Sai-Ching Yeung, Aiham Qdaisat, Mona Kamal, Aisha Al-Breiki, Biman Goswami, Carol C. Wu, Shouhao Zhou, Terry Rice, and Kumar Alagapan

Incidental pulmonary embolisms (IPE) are commonly discovered in cancer patients during their cancer staging and surveillance imaging studies. Examining the clinical characteristics and outcomes of these incidents in cancer patients may guide the

Full access

Alexandre Hikiji Watanabe, Connor Willis, Melissa Pavilack-Kirker, Clara Lam, Leah Park, Sandhya Mehta, Jackie Kwong, Anindit Chhibber, Hillevi Bauer, Sabrina Ilham, Diana Brixner, and David Stenehjem

240 (46.0%) were HER2-low, 142 (27.2%) HER2+, 46 (8.8%) HER2 IHC 0, and 94 (18.0%) had unknown/incomplete HER2 results. Among the HER2-low patients, 198 (82.5%) were HR+, 40 (16.7%) were HR-, and 2 (0.8%) were unknown. The tumor characteristics and